Lymphoma Clinical Trials

Showing 401-420 of 2,926 trials

Application of Telemedicine to the Management of Aggressive Lymphomas

NCT03336138

The purpose of this study is to evaluate the value of AMA in a comparative multicenter regional study as a reference for aggressive lymphoma. The primary endpoint will be RDI. This study consider that the AMA support should allow a significant improvement of the RDI compared to the control group and thus impact the duration without progression. The study covers 350 patients recruited from 10 regional centers.

Lymphoma

University Hospital, Toulouse350 participantsStarted Jan 2012

Toulouse, France, France • Albi, France • Auch, France +7 more locations

COMPLETEDNA

Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency

NCT02553447

This randomized pilot early phase I trial studies how well cholecalciferol works in treating patients with newly diagnosed non-Hodgkin lymphoma or chronic lymphocytic leukemia with low levels of vitamin D (vitamin D deficiency). Cholecalciferol may increase levels of vitamin D and improve survival in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia receiving standard of care chemotherapy.

Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaUntreated Chronic Lymphocytic Leukemia+1 more

University of Nebraska197 participantsStarted Oct 2015

Omaha, Nebraska, United States

Not Yet RecruitingPhase 2

Golidocitinib Combined With GemOx in RR PTCL

NCT07279584

The objective of this study is to evaluate the efficacy and safety of golidocitinib in combination with the GemOx regimen in r/r PTCL

Peripheral T-cell Lymphomas (PTCL)

Ruijin Hospital31 participantsStarted Dec 2025

Application of Telemedicine to the Management of Aggressive Lymphomas

Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency

Golidocitinib Combined With GemOx in RR PTCL

Related Searches

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

STAY-STRONG Study of Exercise Training During Chemotherapy

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Linperlisib Combined With Chidamide in Patients With PTCL

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors